ELEVATE TN: Acalabrutinib ± Obinutuzumab vs Obinutuzumab + Chlorambucil in Treatment-Naive CLL

December 7-10, 2019; Orlando, Florida
Acalabrutinib with or without obinutuzumab significantly improved PFS compared with obinutuzumab plus chlorambucil.
Format: Microsoft PowerPoint (.ppt)
File Size: 208 KB
Released: December 11, 2019

Acknowledgements

Provided by the Annenberg Center for Health Sciences at Eisenhower in partnership with Clinical Care Options.
ACHS Logo

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
Celgene Corporation
Dova Pharmaceuticals, Inc.
Karyopharm Therapeutics
Loxo Oncology, Inc. a wholly owned subsidiary of Eli Lilly and Company
Pharmacyclics LLC, an AbbVie Company
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Related Content

Expert case-based text module on managing toxicities with BCL-2 and PI3K inhibitors in CLL, from Clinical Care Options (CCO)

Nichole Fisher Headshot Nichole Fisher, RN, BSN Nicole Lamanna, MD Anthony Perissinotti, PharmD, BCOP Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: May 19, 2022 Expired: May 18, 2023

On-demand webcast on CAR T-cells for patients with hematologic malignancies, from Clinical Care Options (CCO)

Craig Freyer, PharmD, BCOP Andrew Lin, PharmD, BCOP Pharmacists: 1.0 contact hour (0.1 CEUs) Released: April 28, 2022 Expired: April 27, 2023

Enter the characteristics of your patient with CLL into an online tool from Clinical Care Options (CCO) to see treatment recommendations from 5 experts

Farrukh T. Awan, MD Jennifer R. Brown, MD, PhD Nicole Lamanna, MD Anthony Mato, MD, MSCE Jeff P. Sharman, MD Released: April 26, 2022

An expert provides commentary and recommendations on the clinical needs of HCPs in treating CLL with BTK inhibitors, from Clinical Care Options (CCO)

Jeff P. Sharman, MD Released: April 25, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings